| Hazard Information | Back Directory | [Uses]
Marstacimab (PF-06741086) is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody. Marstacimab can be used for the research of hemophilia[1][2]. | [in vivo]
Marstacimab (0.5 mg/kg; i.v., once) does not affect the blood flow situation in mouse acute bleeding models[2]. | Animal Model: | Acute bleeding hemophilia A mouse models[2] | | Dosage: | 0.5 mg/kg | | Administration: | Intravenous injection, 0.5 mg/kg, once, before tail clip | | Result: | Showed no effect on the blood loss compared with control mice, but significantly reduced the blood loss with the combination of aPCC 200 U/kg.
|
| [References]
[1] Patel-Hett S, et al. Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas. Haemophilia. 2019 Sep;25(5):797-806. DOI:10.1111/hae.13820
[2] Pittman DD, et al. Hemostatic efficacy of marstacimab alone or in combination with bypassing agents in hemophilia plasmas and a mouse bleeding model. Res Pract Thromb Haemost. 2022 Mar 16;6(2):e12679. DOI:10.1002/rth2.12679 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|